Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

The bottom five are (in order from steepest price decline to narrowest): Walgreens Boots Alliance (NASDAQ: WBA), Estée Lauder ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same ...